The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform

Damrong Reinprayoon - One of the best experts on this subject based on the ideXlab platform.

  • the effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to norplant use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p <0.05). The difference was statistically significant. It is concluded that Mefenamic Acid was more effective than placebo in short-term control of irregular bleeding and spotting associated with Norplant use.

  • The effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to Norplant® use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p

Zahangir Alam - One of the best experts on this subject based on the ideXlab platform.

  • Molecular recognition and solubility of Mefenamic Acid in water
    Asian Journal of Chemistry, 2016
    Co-Authors: S K Abdul Mudalip, Fatmawati Adam, Parveen Jamal, M. R. Abu Bakar, Zahangir Alam
    Abstract:

    Molecular dynamics (MD) simulations were performed using COMPASS force field and Ewald summation method that are available in the Material Studio simulation package. The aim of this work is to investigate the solubility and intermolecular interactions (i.e., hydrogen bonding) of water with Mefenamic Acid. The solubility of Mefenamic Acid in water is lower than the ideal solubility. The results of the simulation show that the density, diffusion coefficient and radial distribution functions (RDFs) calculated for water are comparable with the literature. Analysis of radial distribution functions in the binary system of Mefenamic Acid/water shows low hydrogen bond formation between Mefenamic Acid and water molecules as well as diffusivity. In addition, the strength of the interaction is much lower than that of hydrogen bonds formed between molecules of water. These findings suggest low diffusivity and poor solubility characteristic of Mefenamic Acid in water

Srinaree Kaewrudee - One of the best experts on this subject based on the ideXlab platform.

  • the effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to norplant use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p <0.05). The difference was statistically significant. It is concluded that Mefenamic Acid was more effective than placebo in short-term control of irregular bleeding and spotting associated with Norplant use.

  • The effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to Norplant® use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p

S K Abdul Mudalip - One of the best experts on this subject based on the ideXlab platform.

  • Molecular recognition and solubility of Mefenamic Acid in water
    Asian Journal of Chemistry, 2016
    Co-Authors: S K Abdul Mudalip, Fatmawati Adam, Parveen Jamal, M. R. Abu Bakar, Zahangir Alam
    Abstract:

    Molecular dynamics (MD) simulations were performed using COMPASS force field and Ewald summation method that are available in the Material Studio simulation package. The aim of this work is to investigate the solubility and intermolecular interactions (i.e., hydrogen bonding) of water with Mefenamic Acid. The solubility of Mefenamic Acid in water is lower than the ideal solubility. The results of the simulation show that the density, diffusion coefficient and radial distribution functions (RDFs) calculated for water are comparable with the literature. Analysis of radial distribution functions in the binary system of Mefenamic Acid/water shows low hydrogen bond formation between Mefenamic Acid and water molecules as well as diffusivity. In addition, the strength of the interaction is much lower than that of hydrogen bonds formed between molecules of water. These findings suggest low diffusivity and poor solubility characteristic of Mefenamic Acid in water

Unnop Jaisamraun - One of the best experts on this subject based on the ideXlab platform.

  • the effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to norplant use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p <0.05). The difference was statistically significant. It is concluded that Mefenamic Acid was more effective than placebo in short-term control of irregular bleeding and spotting associated with Norplant use.

  • The effect of Mefenamic Acid on controlling irregular uterine bleeding secondary to Norplant® use
    Contraception, 1999
    Co-Authors: Srinaree Kaewrudee, Surasak Taneepanichskul, Unnop Jaisamraun, Damrong Reinprayoon
    Abstract:

    The aim of this double-blind, placebo-controlled study was to evaluate the effect of Mefenamic Acid and placebo on controlling irregular uterine bleeding secondary to Norplant® use. A total of 67 Norplant users attending the Family Planning Clinic of Chulalongkorn Hospital all had irregular bleeding. These women were randomly allocated into two groups. A total 34 users received Mefenamic Acid, 500 mg twice a day for 5 days, and placebos were given to the other 33 in the same manner. The total days of bleeding and spotting and the percentage of women in whom bleeding was stopped were analyzed in weeks 1 and 4. The percentage of subjects in whom bleeding was stopped during week 1 after initial treatment was significantly higher in the Mefenamic Acid group than the placebo group (76%, 27%; p 20 days was found in 68% of the subjects treated with Mefenamic Acid and 33% treated with the placebo; the mean number of bleeding/spotting days was lower with Mefenamic Acid treatment (11.6 and 17.2 days; p